Treatment of Operable Resectable Early-Stage Non-Small Cell Lung Cancer (Stage I, II, or Selected Resectable Stage IIIA)

Patients with non-small cell lung cancer (NSCLC) at clinical stage I, II, or selected resectable stage IIIA who are candidates for surgery represent a distinct population where a curative-intent approach is feasible. The management of these patients follows a structured protocol centred on surgical eligibility and extent of disease.

For operable patients at these stages, surgery provides the best chance for cure — particularly in stage I and II disease. Surgical resection is the primary treatment option for eligible patients, including those with node-negative disease, and forms the foundation of management even in selected resectable stage IIIA presentations.

Treatment Approach — Partial Overview

The standard approach involves anatomic pulmonary resection with lymph node assessment. For certain presentations — such as node-positive or larger tumours — systemic therapy administered prior to surgery may be incorporated into the plan. The full sequence of interventions, eligibility criteria, and decision points are specified in the complete protocol.

Clinical goal: Complete resection with negative margins (R0), confirmed by systematic lymph node evaluation showing no residual mediastinal tumour.

Instant Access to Structured Evidence-Based Regimens

References

View source ↗